These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 21208199)

  • 21. Increased serum levels of soluble CD14 indicate stable multiple sclerosis.
    Lutterotti A; Kuenz B; Gredler V; Khalil M; Ehling R; Gneiss C; Egg R; Deisenhammer F; Berger T; Reindl M
    J Neuroimmunol; 2006 Dec; 181(1-2):145-9. PubMed ID: 17046070
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Natural history of multiple sclerosis: a unifying concept.
    Confavreux C; Vukusic S
    Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alteration of prolyl oligopeptidase and activated α-2-macroglobulin in multiple sclerosis subtypes and in the clinically isolated syndrome.
    Tenorio-Laranga J; Peltonen I; Keskitalo S; Duran-Torres G; Natarajan R; Männistö PT; Nurmi A; Vartiainen N; Airas L; Elovaara I; García-Horsman JA
    Biochem Pharmacol; 2013 Jun; 85(12):1783-94. PubMed ID: 23643808
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increase in CCR5 Delta32/Delta32 genotype in multiple sclerosis.
    Pulkkinen K; Luomala M; Kuusisto H; Lehtimäki T; Saarela M; Jalonen TO; Elovaara I
    Acta Neurol Scand; 2004 May; 109(5):342-7. PubMed ID: 15080861
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression.
    Venken K; Hellings N; Hensen K; Rummens JL; Medaer R; D'hooghe MB; Dubois B; Raus J; Stinissen P
    J Neurosci Res; 2006 Jun; 83(8):1432-46. PubMed ID: 16583400
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intrathecal IgM synthesis in pediatric MS is not a negative prognostic marker of disease progression: quantitative versus qualitative IgM analysis.
    Stauch C; Reiber H; Rauchenzauner M; Strasak A; Pohl D; Hanefeld F; Gärtner J; Rostásy KM
    Mult Scler; 2011 Mar; 17(3):327-34. PubMed ID: 21123302
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A representative cohort of patients with non-progressive multiple sclerosis at the age of normal life expectancy.
    Skoog B; Runmarker B; Winblad S; Ekholm S; Andersen O
    Brain; 2012 Mar; 135(Pt 3):900-11. PubMed ID: 22366800
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma pentosidine: a potential biomarker in the management of multiple sclerosis.
    Sternberg Z; Hennies C; Sternberg D; Bistulfi GL; Kazim L; Benedict RH; Chadha K; Leung C; Weinstock-Guttman B; Munschauer F
    Mult Scler; 2011 Feb; 17(2):157-63. PubMed ID: 20965962
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum homocysteine levels in relation to clinical progression in multiple sclerosis.
    Teunissen CE; Killestein J; Kragt JJ; Polman CH; Dijkstra CD; Blom HJ
    J Neurol Neurosurg Psychiatry; 2008 Dec; 79(12):1349-53. PubMed ID: 18676406
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum uric acid level in patients with relapsing-remitting multiple sclerosis.
    Ashtari F; Bahar M; Aghaei M; Zahed A
    J Clin Neurosci; 2013 May; 20(5):676-8. PubMed ID: 23528410
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The balance of pro-inflammatory and trophic factors in multiple sclerosis patients: effects of acute relapse and immunomodulatory treatment.
    Lindquist S; Hassinger S; Lindquist JA; Sailer M
    Mult Scler; 2011 Jul; 17(7):851-66. PubMed ID: 21561957
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sunlight exposure and sun sensitivity associated with disability progression in multiple sclerosis.
    D'hooghe MB; Haentjens P; Nagels G; Garmyn M; De Keyser J
    Mult Scler; 2012 Apr; 18(4):451-9. PubMed ID: 21952096
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HSP27 and HSP70 serum and urine levels in patients suffering from chronic kidney disease.
    Lebherz-Eichinger D; Ankersmit HJ; Hacker S; Hetz H; Kimberger O; Schmidt EM; Reiter T; Hörl WH; Haas M; Krenn CG; Roth GA
    Clin Chim Acta; 2012 Jan; 413(1-2):282-6. PubMed ID: 22032827
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proteomic pattern analysis discriminates among multiple sclerosis-related disorders.
    Komori M; Matsuyama Y; Nirasawa T; Thiele H; Becker M; Alexandrov T; Saida T; Tanaka M; Matsuo H; Tomimoto H; Takahashi R; Tashiro K; Ikegawa M; Kondo T
    Ann Neurol; 2012 May; 71(5):614-23. PubMed ID: 22522477
    [TBL] [Abstract][Full Text] [Related]  

  • 35. sICAM-1 is not a marker for disease activity in the relapse-free interval of multiple sclerosis--a cross-sectional pilot study.
    Flachenecker P; Jung S; Rieckmann P; Toyka KV
    J Neurol; 2002 Aug; 249(8):1001-3. PubMed ID: 12195444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum levels of sTNFR-1 and sFas in patients with relapsing-remitting multiple sclerosis.
    Bilińska M; Frydecka I; Podemski R; Gruszka E
    Med Sci Monit; 2002 Oct; 8(10):CR720-3. PubMed ID: 12388926
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changes in plasma level of heat shock protein 27 after acute coronary syndrome.
    Heidari-Bakavoli AR; Sahebkar A; Mobara N; Moohebati M; Tavallaie S; Rahsepar AA; Kazemi A; Alavi MS; Ghayour-Mobarhan M; Ferns GA
    Angiology; 2012 Jan; 63(1):12-6. PubMed ID: 21555305
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lower Serum Zinc Levels in Patients with Multiple Sclerosis Compared to Healthy Controls.
    Pawlitzki M; Uebelhör J; Sweeney-Reed CM; Stephanik H; Hoffmann J; Lux A; Reinhold D
    Nutrients; 2018 Jul; 10(8):. PubMed ID: 30049983
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A clinical and laboratory study evaluating the profile of cytokine levels in relapsing remitting and secondary progressive multiple sclerosis.
    Pasquali L; Lucchesi C; Pecori C; Metelli MR; Pellegrini S; Iudice A; Bonuccelli U
    J Neuroimmunol; 2015 Jan; 278():53-9. PubMed ID: 25595252
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neurofilament light as a prognostic marker in multiple sclerosis.
    Salzer J; Svenningsson A; Sundström P
    Mult Scler; 2010 Mar; 16(3):287-92. PubMed ID: 20086018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.